CM3.1-AC100 / Boston Scientific  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CM3.1-AC100 / Boston Scientific
NCT01028521: First in Man Clinical Study to Investigate Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of CM3.1-AC100

Completed
1
56
Europe
CM3.1-AC100, Placebo
CellMed AG, a subsidiary of BTG plc.
Healthy
05/10
05/10
NCT01165502: Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers

Completed
1
40
Europe
CM3.1-AC100, Placebo
CellMed AG, a subsidiary of BTG plc.
Healthy
11/10
11/10
NCT01196728: Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes

Completed
1
16
Europe
CM3.1-AC100
CellMed AG, a subsidiary of BTG plc.
Type II Diabetes Mellitus
11/10
11/10

Download Options